Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Kirstein 3rd Floor, Boston, MA 02215, USA; Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA, USA.
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Kirstein 3rd Floor, Boston, MA 02215, USA; Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA, USA.
Obstet Gynecol Clin North Am. 2023 Mar;50(1):163-182. doi: 10.1016/j.ogc.2022.10.018. Epub 2022 Oct 21.
The COVID-19 pandemic has generated an unprecedented amount of novel and repurposed vaccines and therapeutics that have been rapidly developed and implemented into clinical use. Unfortunately, pregnant persons have been excluded from most phase III clinical studies; therefore, our understanding regarding their safety for use in this population stems from understanding of theoretic risks and observational data. In this review, the authors discuss pregnancy-specific considerations for COVID-19 therapeutics.
译文：COVID-19 大流行产生了大量前所未有的新疫苗和已重新用于治疗 COVID-19 的药物，这些疫苗和药物已被迅速开发并投入临床使用。不幸的是，大多数 III 期临床试验都排除了孕妇；因此，我们对这些药物在该人群中使用安全性的了解源自对理论风险和观察性数据的理解。在这篇综述中，作者讨论了 COVID-19 治疗药物的妊娠相关注意事项。
